Skip to main content
. 2021 Jan 11;10:606412. doi: 10.3389/fcimb.2020.606412

Figure 1.

Figure 1

A model for EBV-positive Burkitt lymphomagenesis. Cells transformed with EBV are provided with oncogenic advantages including the ability to proliferate and the ability to avoid apoptosis through the expression of viral transforming genes. However, EBV infected cells are targeted by the host’s immune system. As mutations randomly accumulate in cells, they allow expression of some of EBV’s genes to be turned off if compensated by such cellular mutations and reduce immune-mediated tumor cell killing.